GLP-1 / Metabolic
Liraglutide
Also known as: Victoza
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). It was the first GLP-1 analog approved for obesity and carries an FDA boxed warning for the risk of thyroid C-cell tumors. Pediatric indications include type 2 diabetes in patients ≥10 years (Victoza) and obesity in patients ≥12 years with BMI ≥95th percentile (Saxenda).
Vendors carrying Liraglutide
0 listings, ranked by trust score
Each row is a (vendor, peptide) pair. Click through for the listing detail, the vendor's full trust profile, and any COAs they've published.
No vendors carrying this peptide are indexed yet.
Independent evidence
No COAs on file for Liraglutide
No third-party tests indexed yet. Phase 2 will surface more vendor evidence as the dataset grows.